SCHEMBL291198

SCHEMBL291198

Cc1cc(Nc2ccc3c(c2)c(N)cc(C)[n+]3C)nc(N)[n+]1C

nearest known ligand 0.67

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TERT O14746 11/20 0.67
DOT1L Q8TEK3 4/20 0.42
ALOX15 P16050 2/20 0.42
RAB9A P51151 2/20 0.33
CYP1A2 P05177 2/20 0.33
NPC1 O15118 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C19 P33261 1/20 0.33
RAC1 P63000 1/20 0.32
CYP2D6 P10635 1/20 0.32
MEN1 O00255 1/20 0.32
MMP1 P03956 1/20 0.32
MMP9 P14780 1/20 0.32
BLM P54132 1/20 0.32
GNG2 P59768 1/20 0.32
GNB1 P62873 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sulfuric Acid SCHEMBL8658789 0.93 TERT (0.59) TERTDOT1LALOX15MEN1MMP1
Pyritidium SCHEMBL29387282 0.73 MEN1 (0.49) TERTDOT1LALOX15RAB9ACYP1A2
Iodide SCHEMBL9380644 0.73 ROCK1 (0.52) TERTRAB9ACYP1A2NPC1CYP3A4
Pyritidium SCHEMBL30468818 0.73 MEN1 (0.51) TERTDOT1LALOX15RAB9ACYP1A2
Pyritidium SCHEMBL2732830 0.73 MEN1 (0.51) TERTDOT1LALOX15RAB9ACYP1A2
SCHEMBL291197 0.72 TERT (0.54) TERTDOT1LALOX15
Pyritidium SCHEMBL7636972 0.71 MEN1 (0.49) TERTDOT1LALOX15RAB9ACYP1A2
Iodide SCHEMBL3500716 0.71 NPC1 (0.49) RAB9ANPC1MEN1KMT2A
SCHEMBL3239601 0.70 MMP9 (0.54) ALOX15MEN1MMP1MMP9BLM
SCHEMBL6600083 0.70 TERT (0.54) TERTALOX15RAB9ACYP1A2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 534 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250312349-A1 COMPOSITION AND METHODS OF TREATING INTRACELLULAR PATHOGEN INFECTION UNIV HOSPITALS CLEVELAND MEDICAL CENTER (US) 2025-10-09 US claimed
EP-4323054-A1 CATHETERS INCLUDING METALLIC ALLOYS FOR INTRODUCTION OF THERAPEUTIC IONS Rain Scientific, Inc. (US) 2024-02-21 EP claimed
WO-2022221287-A1 CATHETERS INCLUDING METALLIC ALLOYS FOR INTRODUCTION OF THERAPEUTIC IONS RAIN SCIENTIFIC, INC. (US) 2022-10-20 WO claimed
US-20170291886-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS NEOCULI PTY LTD (AU) 2017-10-12 US claimed
US-20090131342-A1 Nitrosated and/or nitrosylated compounds, compositions and methods of use NITROMED, INC. (US) 2009-05-21 US claimed
EP-1718286-A2 NITROSATED AND/OR NITROSYLATED COMPOUNDS, COMPOSITIONS AND METHODS OF USE Nitromed, Inc. (US) 2006-11-08 EP claimed
WO-2005070006-A2 NITROSATED AND/OR NITROSYLATED COMPOUNDS, COMPOSITIONS AND METHODS OF USE NITROMED, INC. (US) 2005-08-04 WO claimed
US-20030105066-A1 Nitrate salts of antimicrobial agents NICOX S.A. (FR) 2003-06-05 US claimed
EP-1253924-A1 NITRATE SALTS OF ANTIMICROBIAL AGENTS NICOX S.A. (FR) 2002-11-06 EP claimed
WO-2001054691-A1 NITRATE SALTS OF ANTIMICROBIAL AGENTS NICOX, S.A. (FR) 2001-08-02 WO claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
EP-0193414-A2 Liposomes, process for their preparation and compositions containing them Fluck, David John (ZW) 1986-09-03 EP claimed
WO-2026110111-A1 DIAZO COMPOUNDS WITH ANTI-TRYPANOSOMAL ACTIVITIES INDIAN COUNCIL OF AGRICULTURAL RESEARCH (IN) 2026-05-28 WO disclosed
EP-4094767-B1 NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO UNIV EMORY (US) 2026-05-20 EP disclosed
EP-3448392-B1 ALKYNE CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO UNIV EMORY (US) 2026-05-13 EP disclosed
EP-0193414-A3 LIPOSOMES, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM Fluck, David John (ZW) 1987-02-04 EP disclosed
EP-0193414-A2 Liposomes, process for their preparation and compositions containing them Fluck, David John (ZW) 1986-09-03 EP disclosed
EP-0193414-A2 Liposomes, process for their preparation and compositions containing them Fluck, David John (ZW) 1986-09-03 EP disclosed
US-4399151-A USING A-SUBSTITUTERD AMINES OR A-SUBSTITUTED AMINO ACIDS MERRELL DOW PHARMACEUTICALS INC. (US) 1983-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131342-A1 Nitrosated and/or nitrosylated compounds, compositions and methods of use LTC4S, LTB4R2, LTB4R TERT 829/4885DOT1L 4721/4885ALOX15 57/4885
US-20170291886-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS DPM1, ABCB11, PIGS TERT 1265/4885DOT1L 3772/4885ALOX15 1108/4885
US-20030105066-A1 Nitrate salts of antimicrobial agents NOS1, NOS3, NOS2 TERT 4342/4885DOT1L 4640/4885ALOX15 3058/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.